Probing the mystery of drug supply disruption
Philadelphia Inquirer, October 24, 2011
Leflunomide offers a big window onto some worrisome trends in the pharmaceutical industry, including manufacturing problems and drug shortages that can result not just in price spikes, but in big disruptions in patient care - sometimes even deaths.It's not entirely clear why leflunomide became scarce, or who benefited from the price increases. The good news is that at least they appear to have been temporary. One clear factor in the shortage was a suspension in imports by Apotex, the U.S. arm of a Canadian maker of generics, after inspectors from the U.S. Food and Drug Administration found problems at two of its Toronto facilities in September 2009.
Most Viewed
Most Emailed
- Urologists 'Outraged' Over PSA Test Challenge
- New Facebook Page Gathers Stories of Medical Harm
- Luxury Hospital Facilities Put Patient Experience First
- Five Hospitals Share Three Secrets to Improve Knee Surgery Outcomes
- Heartland Health Joins Mayo Clinic Network
- Beleaguered Fairview Health CEO to Retire in July
- Health Insurance Exchanges Put Defined Benefits to the Test
- Challenging Physicians to Help Improve the ED
- For hospitals and insurers, new fervor to cut costs
- How Rivals Built an ACO

